Loading…

DNA Amplification of HER-2/neu and INT-2 Oncogenes in Epithelial Ovarian Cancer

Objective: Oncogene alterations are thought to be prognostic indices in patients with breast cancer. The present study was carried out to investigate the amplification of the HER-2/neu and INT-2 oncogenes in ovarian cancer. Methods: In a retrospective study of 196 patients with epithelial ovarian ca...

Full description

Saved in:

Bibliographic Details
Published in:	Gynecologic oncology 1995-12, Vol.59 (3), p.321-326
Main Authors:	Medl, Michael, Sevelda, Paul, Czerwenka, Klaus, Dobianer, Karl, Hanak, Hanns, Hruza, Christa, Klein, Matthias, Leodolter, Sepp, Müllauer-Ertl, Susanne, Rosen, Alexander, Salzer, Heinrich, Vavra, Norbert, Spona, Jürgen
Format:	Article
Language:	English
Subjects:	Adolescent Adult Aged Aged, 80 and over Base Sequence Biological and medical sciences DNA, Neoplasm - genetics Female Female genital diseases Fibroblast Growth Factor 3 Fibroblast Growth Factors - genetics Gene Amplification Genes, erbB-2 Gynecology. Andrology. Obstetrics Humans Medical sciences Middle Aged Molecular Probes - genetics Molecular Sequence Data Ovarian Neoplasms - genetics Ovarian Neoplasms - mortality Proto-Oncogene Proteins - genetics Retrospective Studies Survival Analysis Tumors
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c368t-70ba9b26829a83c61d8a83e2a5951d40cefdf5eca7e61102ef054eac8bc1bbbd3
cites
container_end_page	326
container_issue	3
container_start_page	321
container_title	Gynecologic oncology
container_volume	59
creator	Medl, Michael Sevelda, Paul Czerwenka, Klaus Dobianer, Karl Hanak, Hanns Hruza, Christa Klein, Matthias Leodolter, Sepp Müllauer-Ertl, Susanne Rosen, Alexander Salzer, Heinrich Vavra, Norbert Spona, Jürgen
description	Objective: Oncogene alterations are thought to be prognostic indices in patients with breast cancer. The present study was carried out to investigate the amplification of the HER-2/neu and INT-2 oncogenes in ovarian cancer. Methods: In a retrospective study of 196 patients with epithelial ovarian cancer, the amplification of the oncogenes HER-2/neu and INT-2 in the DNA of paraffin-embedded tumor cells was determined by quantitative PCR. The purpose of this study was to analyze whether the two oncogenes correlated with such predictive factors as FIGO stage, histological grade, ascites, postoperative residual tumor mass, hormone receptor content, and preoperative CA 125 serum levels. The effect of HER-2/neu and INT-2 amplification on patient survival was also studied. Results: The only correlation found in this study was between INT-2 and preoperative CA 125 levels (P= 0.03). No correlations were demonstrable between HER-2/neu (log-rank test;P= 0.67) and INT-2 (log-rank test;P= 0.75) amplifications and overall survival. Conclusion: Unlike the established prognostic factors, neither HER-2/neu nor INT-2 appears to be predictive for survival in patients with ovarian cancer.
doi_str_mv	10.1006/gyno.1995.9969
format	article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77727482</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825885799696</els_id><sourcerecordid>77727482</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-70ba9b26829a83c61d8a83e2a5951d40cefdf5eca7e61102ef054eac8bc1bbbd3</originalsourceid><addsrcrecordid>eNp1kMFPwjAUhxujQUSv3kx6MN4GbUe39kgQhYRAYvDcdN0b1owO242E_95NCDdP7_D73i_vfQg9UjKkhCSj7dFVQyolH0qZyCvUp0TyKBFcXqM-IZJEgnFxi-5C-CaExISyHuoJzhgbiz5av64meLLbl7awRte2crgq8Hz2EbGRgwZrl-PFahMxvHam2oKDgK3Ds72tv6C0usTrg_ZWOzzVzoC_RzeFLgM8nOcAfb7NNtN5tFy_L6aTZWTiRNRRSjItM5YIJrWITUJz0U5gmktO8zExUOQFB6NTSCglDArCx6CNyAzNsiyPB-jl1Lv31U8DoVY7GwyUpXZQNUGlacrSsWAtODyBxlcheCjU3tud9kdFieoMqs6g6gyqzmC78HRubrId5Bf8rKzNn8-5DkaXhW__tuGCMcni9A8TJwxaCwcLXgVjoVWUWw-mVnll_7vgF1yzi2g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77727482</pqid></control><display><type>article</type><title>DNA Amplification of HER-2/neu and INT-2 Oncogenes in Epithelial Ovarian Cancer</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Medl, Michael ; Sevelda, Paul ; Czerwenka, Klaus ; Dobianer, Karl ; Hanak, Hanns ; Hruza, Christa ; Klein, Matthias ; Leodolter, Sepp ; Müllauer-Ertl, Susanne ; Rosen, Alexander ; Salzer, Heinrich ; Vavra, Norbert ; Spona, Jürgen</creator><creatorcontrib>Medl, Michael ; Sevelda, Paul ; Czerwenka, Klaus ; Dobianer, Karl ; Hanak, Hanns ; Hruza, Christa ; Klein, Matthias ; Leodolter, Sepp ; Müllauer-Ertl, Susanne ; Rosen, Alexander ; Salzer, Heinrich ; Vavra, Norbert ; Spona, Jürgen</creatorcontrib><description>Objective: Oncogene alterations are thought to be prognostic indices in patients with breast cancer. The present study was carried out to investigate the amplification of the HER-2/neu and INT-2 oncogenes in ovarian cancer. Methods: In a retrospective study of 196 patients with epithelial ovarian cancer, the amplification of the oncogenes HER-2/neu and INT-2 in the DNA of paraffin-embedded tumor cells was determined by quantitative PCR. The purpose of this study was to analyze whether the two oncogenes correlated with such predictive factors as FIGO stage, histological grade, ascites, postoperative residual tumor mass, hormone receptor content, and preoperative CA 125 serum levels. The effect of HER-2/neu and INT-2 amplification on patient survival was also studied. Results: The only correlation found in this study was between INT-2 and preoperative CA 125 levels (P= 0.03). No correlations were demonstrable between HER-2/neu (log-rank test;P= 0.67) and INT-2 (log-rank test;P= 0.75) amplifications and overall survival. Conclusion: Unlike the established prognostic factors, neither HER-2/neu nor INT-2 appears to be predictive for survival in patients with ovarian cancer.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1006/gyno.1995.9969</identifier><identifier>PMID: 8522248</identifier><identifier>CODEN: GYNOA3</identifier><language>eng</language><publisher>San Diego, CA: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Base Sequence ; Biological and medical sciences ; DNA, Neoplasm - genetics ; Female ; Female genital diseases ; Fibroblast Growth Factor 3 ; Fibroblast Growth Factors - genetics ; Gene Amplification ; Genes, erbB-2 ; Gynecology. Andrology. Obstetrics ; Humans ; Medical sciences ; Middle Aged ; Molecular Probes - genetics ; Molecular Sequence Data ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - mortality ; Proto-Oncogene Proteins - genetics ; Retrospective Studies ; Survival Analysis ; Tumors</subject><ispartof>Gynecologic oncology, 1995-12, Vol.59 (3), p.321-326</ispartof><rights>1995</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-70ba9b26829a83c61d8a83e2a5951d40cefdf5eca7e61102ef054eac8bc1bbbd3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2923748$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8522248$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Medl, Michael</creatorcontrib><creatorcontrib>Sevelda, Paul</creatorcontrib><creatorcontrib>Czerwenka, Klaus</creatorcontrib><creatorcontrib>Dobianer, Karl</creatorcontrib><creatorcontrib>Hanak, Hanns</creatorcontrib><creatorcontrib>Hruza, Christa</creatorcontrib><creatorcontrib>Klein, Matthias</creatorcontrib><creatorcontrib>Leodolter, Sepp</creatorcontrib><creatorcontrib>Müllauer-Ertl, Susanne</creatorcontrib><creatorcontrib>Rosen, Alexander</creatorcontrib><creatorcontrib>Salzer, Heinrich</creatorcontrib><creatorcontrib>Vavra, Norbert</creatorcontrib><creatorcontrib>Spona, Jürgen</creatorcontrib><title>DNA Amplification of HER-2/neu and INT-2 Oncogenes in Epithelial Ovarian Cancer</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Objective: Oncogene alterations are thought to be prognostic indices in patients with breast cancer. The present study was carried out to investigate the amplification of the HER-2/neu and INT-2 oncogenes in ovarian cancer. Methods: In a retrospective study of 196 patients with epithelial ovarian cancer, the amplification of the oncogenes HER-2/neu and INT-2 in the DNA of paraffin-embedded tumor cells was determined by quantitative PCR. The purpose of this study was to analyze whether the two oncogenes correlated with such predictive factors as FIGO stage, histological grade, ascites, postoperative residual tumor mass, hormone receptor content, and preoperative CA 125 serum levels. The effect of HER-2/neu and INT-2 amplification on patient survival was also studied. Results: The only correlation found in this study was between INT-2 and preoperative CA 125 levels (P= 0.03). No correlations were demonstrable between HER-2/neu (log-rank test;P= 0.67) and INT-2 (log-rank test;P= 0.75) amplifications and overall survival. Conclusion: Unlike the established prognostic factors, neither HER-2/neu nor INT-2 appears to be predictive for survival in patients with ovarian cancer.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Base Sequence</subject><subject>Biological and medical sciences</subject><subject>DNA, Neoplasm - genetics</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Fibroblast Growth Factor 3</subject><subject>Fibroblast Growth Factors - genetics</subject><subject>Gene Amplification</subject><subject>Genes, erbB-2</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Probes - genetics</subject><subject>Molecular Sequence Data</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Tumors</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNp1kMFPwjAUhxujQUSv3kx6MN4GbUe39kgQhYRAYvDcdN0b1owO242E_95NCDdP7_D73i_vfQg9UjKkhCSj7dFVQyolH0qZyCvUp0TyKBFcXqM-IZJEgnFxi-5C-CaExISyHuoJzhgbiz5av64meLLbl7awRte2crgq8Hz2EbGRgwZrl-PFahMxvHam2oKDgK3Ds72tv6C0usTrg_ZWOzzVzoC_RzeFLgM8nOcAfb7NNtN5tFy_L6aTZWTiRNRRSjItM5YIJrWITUJz0U5gmktO8zExUOQFB6NTSCglDArCx6CNyAzNsiyPB-jl1Lv31U8DoVY7GwyUpXZQNUGlacrSsWAtODyBxlcheCjU3tud9kdFieoMqs6g6gyqzmC78HRubrId5Bf8rKzNn8-5DkaXhW__tuGCMcni9A8TJwxaCwcLXgVjoVWUWw-mVnll_7vgF1yzi2g</recordid><startdate>19951201</startdate><enddate>19951201</enddate><creator>Medl, Michael</creator><creator>Sevelda, Paul</creator><creator>Czerwenka, Klaus</creator><creator>Dobianer, Karl</creator><creator>Hanak, Hanns</creator><creator>Hruza, Christa</creator><creator>Klein, Matthias</creator><creator>Leodolter, Sepp</creator><creator>Müllauer-Ertl, Susanne</creator><creator>Rosen, Alexander</creator><creator>Salzer, Heinrich</creator><creator>Vavra, Norbert</creator><creator>Spona, Jürgen</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19951201</creationdate><title>DNA Amplification of HER-2/neu and INT-2 Oncogenes in Epithelial Ovarian Cancer</title><author>Medl, Michael ; Sevelda, Paul ; Czerwenka, Klaus ; Dobianer, Karl ; Hanak, Hanns ; Hruza, Christa ; Klein, Matthias ; Leodolter, Sepp ; Müllauer-Ertl, Susanne ; Rosen, Alexander ; Salzer, Heinrich ; Vavra, Norbert ; Spona, Jürgen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-70ba9b26829a83c61d8a83e2a5951d40cefdf5eca7e61102ef054eac8bc1bbbd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Base Sequence</topic><topic>Biological and medical sciences</topic><topic>DNA, Neoplasm - genetics</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Fibroblast Growth Factor 3</topic><topic>Fibroblast Growth Factors - genetics</topic><topic>Gene Amplification</topic><topic>Genes, erbB-2</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Probes - genetics</topic><topic>Molecular Sequence Data</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Medl, Michael</creatorcontrib><creatorcontrib>Sevelda, Paul</creatorcontrib><creatorcontrib>Czerwenka, Klaus</creatorcontrib><creatorcontrib>Dobianer, Karl</creatorcontrib><creatorcontrib>Hanak, Hanns</creatorcontrib><creatorcontrib>Hruza, Christa</creatorcontrib><creatorcontrib>Klein, Matthias</creatorcontrib><creatorcontrib>Leodolter, Sepp</creatorcontrib><creatorcontrib>Müllauer-Ertl, Susanne</creatorcontrib><creatorcontrib>Rosen, Alexander</creatorcontrib><creatorcontrib>Salzer, Heinrich</creatorcontrib><creatorcontrib>Vavra, Norbert</creatorcontrib><creatorcontrib>Spona, Jürgen</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Medl, Michael</au><au>Sevelda, Paul</au><au>Czerwenka, Klaus</au><au>Dobianer, Karl</au><au>Hanak, Hanns</au><au>Hruza, Christa</au><au>Klein, Matthias</au><au>Leodolter, Sepp</au><au>Müllauer-Ertl, Susanne</au><au>Rosen, Alexander</au><au>Salzer, Heinrich</au><au>Vavra, Norbert</au><au>Spona, Jürgen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DNA Amplification of HER-2/neu and INT-2 Oncogenes in Epithelial Ovarian Cancer</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>1995-12-01</date><risdate>1995</risdate><volume>59</volume><issue>3</issue><spage>321</spage><epage>326</epage><pages>321-326</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><coden>GYNOA3</coden><abstract>Objective: Oncogene alterations are thought to be prognostic indices in patients with breast cancer. The present study was carried out to investigate the amplification of the HER-2/neu and INT-2 oncogenes in ovarian cancer. Methods: In a retrospective study of 196 patients with epithelial ovarian cancer, the amplification of the oncogenes HER-2/neu and INT-2 in the DNA of paraffin-embedded tumor cells was determined by quantitative PCR. The purpose of this study was to analyze whether the two oncogenes correlated with such predictive factors as FIGO stage, histological grade, ascites, postoperative residual tumor mass, hormone receptor content, and preoperative CA 125 serum levels. The effect of HER-2/neu and INT-2 amplification on patient survival was also studied. Results: The only correlation found in this study was between INT-2 and preoperative CA 125 levels (P= 0.03). No correlations were demonstrable between HER-2/neu (log-rank test;P= 0.67) and INT-2 (log-rank test;P= 0.75) amplifications and overall survival. Conclusion: Unlike the established prognostic factors, neither HER-2/neu nor INT-2 appears to be predictive for survival in patients with ovarian cancer.</abstract><cop>San Diego, CA</cop><pub>Elsevier Inc</pub><pmid>8522248</pmid><doi>10.1006/gyno.1995.9969</doi><tpages>6</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0090-8258
ispartof	Gynecologic oncology, 1995-12, Vol.59 (3), p.321-326
issn	0090-8258 1095-6859
language	eng
recordid	cdi_proquest_miscellaneous_77727482
source	ScienceDirect Freedom Collection 2022-2024
subjects	Adolescent Adult Aged Aged, 80 and over Base Sequence Biological and medical sciences DNA, Neoplasm - genetics Female Female genital diseases Fibroblast Growth Factor 3 Fibroblast Growth Factors - genetics Gene Amplification Genes, erbB-2 Gynecology. Andrology. Obstetrics Humans Medical sciences Middle Aged Molecular Probes - genetics Molecular Sequence Data Ovarian Neoplasms - genetics Ovarian Neoplasms - mortality Proto-Oncogene Proteins - genetics Retrospective Studies Survival Analysis Tumors
title	DNA Amplification of HER-2/neu and INT-2 Oncogenes in Epithelial Ovarian Cancer
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T14%3A04%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DNA%20Amplification%20of%20HER-2/neu%20and%20INT-2%20Oncogenes%20in%20Epithelial%20Ovarian%20Cancer&rft.jtitle=Gynecologic%20oncology&rft.au=Medl,%20Michael&rft.date=1995-12-01&rft.volume=59&rft.issue=3&rft.spage=321&rft.epage=326&rft.pages=321-326&rft.issn=0090-8258&rft.eissn=1095-6859&rft.coden=GYNOA3&rft_id=info:doi/10.1006/gyno.1995.9969&rft_dat=%3Cproquest_cross%3E77727482%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c368t-70ba9b26829a83c61d8a83e2a5951d40cefdf5eca7e61102ef054eac8bc1bbbd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=77727482&rft_id=info:pmid/8522248&rfr_iscdi=true